Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: New investigation capabilities for clinical pharmacology

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 11, 2014, Pages 2627-2640

  Dahmane, Elyes ^a,b   Boccard, Julien ^a   Csajka, Chantal ^a,b   Rudaz, Serge ^a   Décosterd, Laurent ^b   Genin, Eric ^c   Duretz, Bénédicte ^c   Bromirski, Maciej ^c   Zaman, Khalil ^b   Testa, Bernard ^b   Rochat, Bertrand ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Drug metabolites; High resolution mass spectrometry; Plasma; Quantification; Therapeutic drug monitoring; Triple quadrupole

Indexed keywords

BIOMOLECULES; CARBOHYDRATES; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MULTIVARIANT ANALYSIS; PATIENT MONITORING; PATIENT TREATMENT; PLASMA (HUMAN); PLASMAS;

DRUG METABOLITES; HIGH RESOLUTION MASS SPECTROMETRY; QUANTIFICATION; THERAPEUTIC DRUG MONITORING; TRIPLE QUADRUPOLE;

METABOLITES;

ANTINEOPLASTIC AGENT; TAMOXIFEN;

BLOOD; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL PHARMACOLOGY; DRUG MONITORING; EVALUATION STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLISM; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PHARMACOLOGY, CLINICAL; TAMOXIFEN;

EID: 84898027570     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7682-2     Document Type: Article

References (39)

1. Committee on Quality of Health Care in America To Err Is Human (2000) Building a Safer Health System. In: Kohn LT, Corrigan JM, Donaldson MS (eds) National Academy Press. Washington, DC
2. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. U.S. Food and Drug Administration. Accessed 30 Oct. 2013. http://www.fda.gov/drugs/ developmentapprovalprocess/developmentresources/druginteractionslabeling/ ucm110632.htm
3. Gautier S, Bachelet H, Bordet R, Caron J (2003) The cost of adverse drug reactions. Expert Opin Pharmacother 4:319-326
4. U.S. Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites. Accessed 30 Oct. 2013. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
5. International Conference on Harmonisation. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). Accessed 30 Oct 2013. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf
6. Gao H, Obach RS (2011) Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals. Curr Drug Metab 12:578-586
7. Testa B, Krämer SD (2009) The biochemistry of drug metabolism - an introduction: part 5. Metabolism and bioactivity. Chem Biodivers 6:591-684
8. Stachulski AV, Baillie TA, Kevin Park B, Scott Obach R, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CE, Chia AJ, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS (2013) The generation, detection, and effects of reactive drug metabolites. Med Res Rev 33:985-1080
9. Guengerich FP (2011) Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 26:3-14
10. Krämer SD, Testa B (2008) The biochemistry of drug metabolism - an introduction: part 6. Inter-individual factors affecting drug metabolism. Chem Biodivers 5:2465-2578
11. Krämer SD, Testa B (2009) The biochemistry of drug metabolism - an introduction: part 7. Intra-individual factors affecting drug metabolism. Chem Biodivers 6:1477-1660
12. The importance of pharmacovigilance. Safety Monitoring of medicinal products. World Health Organization 2002 http://apps.who.int/medicinedocs/pdf/ s4893e/s4893e.pdf
13. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159
14. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
15. Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349-366
16. Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JH, Schinkel AH, Beijnen JH (2011) Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J Pharm Biomed Anal 55:518-526
17. Testa B, Pedretti A, Vistoli G (2012) Reactions and enzymes in the metabolism of drugs and other xenobiotics - a meta-analysis of the primary literature. Drug Discov Today 17:549-560
18. Teunissen SF, Rosing H, Schinkel AH, Schellens JH, Beijnen JH (2010) Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. Anal Chim Acta 683:21-37
19. Kaufmann A, Butcher P, Maden K, Walker S, Widmer M (2011) Quantitative and confirmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared to tandem mass spectrometry. Rapid Commun Mass Spectrom 25:979-992
20. Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B (2012) Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun Mass Spectrom 26:499-509
21. Ramanathan R, Korfmacher W (2012) The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis 4:467-469
22. Rochat B, Kottelat E, McMullen J (2012) The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis 4:2939-2958
23. Kaufmann A, Butcher P, Maden K, Walker S, Widmer M (2010) Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry) "where is the crossover point?". Anal Chim Acta 673:60-72
24. Rochat B (2012) Quantitative/qualitative analysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice. Bioanalysis 4:1709-1711
25. FDA Adverse Event Reporting System (FAERS) and European database of suspected adverse reaction reports. Human Drug Information. Division of Drug Information (CDER). Accessed 30 Oct. 2013. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm
26. European Medicines Agency. Accessed 30 Oct. 2013. http://www.ema.europa. eu/docs/en-GB/document-library/Press-release/2012/05/WC500127957.pdf http://www.adrreports.eu
27. Dahmane E, Mercier T, Zanolari B, Cruchon S, Guignard N, Buclin T, Leyvraz S, Zaman K, Csajka C, Decosterd LA (2010) An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4′-hydroxylated metabolites in breast cancer patients. J Chromatogr B Anal Technol Biomed Life Sci 878:3402-3414
28. Anari MR, Sanchez RI, Bakhtiar R, Franklin RB, Baillie TA (2004) Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. Anal Chem 76:823-832
29. Chen G, Yin S, Maiti S, Shao X (2002) 4-hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16:279-285
30. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
31. Testa B, Krämer SD (2007) The biochemistry of drug metabolism - an introduction. Part 2: redox reactions and their enzymes. Chem Biodivers 4:257-405
32. Tang BK (1990) Drug glucosidation. Pharmacol Ther 46:53-56
33. Testa B, Krämer SD (2008) The biochemistry of drug metabolism - an introduction. Part 4: reactions of conjugation and their enzymes. Chem Biodivers 5:2171-2336
34. Bock KW (2003) Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem Pharmacol 66:691-696
35. A receptor antagonist in human liver microsomes. Drug Metab Dispos 31:37-45
36. 4 receptor agonist for gastrointestinal motility disorders. Drug Metab Dispos 39:1170-1180
37. Rochat B, Fayet F, Widmer N, Lahrichi S, Pesse B, Décosterd L, Biollaz J (2008) Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using Liquid chromatography-mass spectrometry. J Mass Spectrom 43:736-752
38. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A (2012) Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 16:R136-R140
39. The International Association of Forensic Toxicologists. Accessed 30 Oct. 2013. http://www.gtfch.org/cms/images/stories/Updated-TIAFT-list-202005.pdf